-
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365 ·
Phase: Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Charlotte, Durham
-
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT06906562 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Raleigh
-
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
NCT07024615 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Winston-Salem
-
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Winston-Salem
-
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Charlotte, Hillsborough
-
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Clinton, Goldsboro, Jacksonville
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT07360314 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
NCT05376592 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Winston-Salem
-
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Pinehurst
-
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT06158139 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
NCT06483555 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Asheville, Cary, Clinton, Clyde
-
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573 ·
Phase: Not specified ·
Ages: 50 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham, Greenville, Hillsborough
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· North Carolina: Durham, Wilson
-
Distance-Based Exercise to Preserve Function and Prevent Disability
NCT07059884 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Kernersville, Mount Airy, Winston-Salem
-
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
NCT05431270 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Increasing Germline Genetic Testing for Patients With Cancer
NCT07307664 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Durham, Salisbury
-
Integrated Cancer Repository for Cancer Research
NCT02012699 ·
Phase: Not specified ·
Ages: 19 Years to 110 Years ·
Sex: All (male and female)
· North Carolina: Fayetteville
-
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Greenville, Winston-Salem
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
NCT06807437 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Concord
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT05076760 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Promoting CT Engagement for Pancreatic Cancer With App
NCT06252545 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Winston-Salem
-
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
NCT05482893 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
NCT05776524 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
NCT04195347 ·
Phase: Phase 1, Phase 2 ·
Ages: Up to 21 Years ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Huntersville
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05005403 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Huntersville
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Clinton, Goldsboro, Jacksonville, Pinehurst
-
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Clemmons, Wilkesboro, Winston-Salem
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03454035 ·
Phase: Phase 1 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham